EADV Congress 2025 Poster Presentation: Zabalafin Hydrogel – A Novel, Safe, and Effective Topical Botanical Drug That Comprehensively Addresses the Four Demons of Atopic Dermatitis

Clinical Presentations

EADV Congress 2025 Poster Presentation: Zabalafin Hydrogel – A Novel, Safe, and Effective Topical Botanical Drug That Comprehensively Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics September 23, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

2025 Integrative Dermatology Summit Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis

Clinical Presentations

2025 Integrative Dermatology Summit Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics August 12, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

50th Annual Society for Pediatric Dermatology Meeting Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis

Clinical Presentations

50th Annual Society for Pediatric Dermatology Meeting Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 22, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal

Press Release

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal NEWS PROVIDED BY Alphyn Biologics Jul 01, 2025, 07:30 ET Expert dermatologist panel creates new atopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD’s intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization…

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis

Clinical Presentations

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis, starting with infection in children and adults NEWS PROVIDED BY Alphyn Biologics May 29, 2025, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195